Screener
Nurix Therapeutics, Inc. NRIX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2025.
- Filed
- Jul 9, 2025
- Fiscal quarter
- Q2 FY2025
- Calendar quarter
- Q2 2025
- Accession
- 0001549595-25-000095
| Line item | May 31,2025 | November 30,2024 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $84,260 | $109,997 |
| Marketable securities, current | 401,521 | 499,586 |
| Accounts receivable | 19,000 | — |
| Prepaid expenses and other current assets | 10,549 | 9,804 |
| Total current assets | 515,330 | 619,387 |
| Operating lease right-of-use assets | 50,214 | 28,139 |
| Property and equipment, net | 18,773 | 17,757 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Nurix Therapeutics, Inc.'s accounts receivable?
- Nurix Therapeutics, Inc. (NRIX) reported accounts receivable of $19M in Q1 2025.
- What is the long-term trend for Nurix Therapeutics, Inc.'s accounts receivable?
- Over 4 years (2020 to 2024), Nurix Therapeutics, Inc.'s accounts receivable has grown at a -100.0% compound annual growth rate (CAGR), from $7.5M to $0.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Nurix Therapeutics, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude